Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Published Online
on April 10, 2008

Arteriosclerosis, Thrombosis, and Vascular Biology. 2008
Published online before print April 10, 2008, doi: 10.1161/ATVBAHA.108.165845
A more recent version of this article appeared on July 1, 2008
This Article
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
28/7/1298    most recent
ATVBAHA.108.165845v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Komori, H.
Right arrow Articles by Ueda, Y.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Komori, H.
Right arrow Articles by Ueda, Y.

Submitted on October 11, 2007
Accepted on March 20, 2008

Coexpression of CLA-1 and Human PDZK1 in Murine Liver Modulates HDL Cholesterol Metabolism

Hidenori Komori ; Hidenori Arai *; Terumi Kashima ; Thierry Huby ; Toru Kita ; and Yukihiko Ueda

From the Departments of Cardiovascular Medicine (H.K., T.K., Y.U.), and Geriatric Medicine (H.A.), Kyoto University Graduate School of Medicine, Japan; Shiga Medical Center Research Institute (T.K.), Moriyama, Japan; and INSERM U551 (T.H.), Dyslipoproteinemia and Atherosclerosis Research Unit, Hôpital de la Pitié, Paris, France.

* To whom correspondence should be addressed. E-mail: harai{at}kuhp.kyoto-u.ac.jp.

Objective—In rodents scavenger receptor class B type I (SR-BI) is a key molecule for selective uptake of cholesteryl ester from high-density lipoprotein (HDL). This study was aimed to clarify the role of the human SR-BI/CD36 and LIMP-II Analogues-1 (CLA-1) as a molecular target of selective uptake of cholesteryl ester from HDL in vivo.

Methods and Results—To clarify the function and regulation of CLA-1 in vivo we produced CLA-1 BAC transgenic mice. In spite of abundant hepatic RNA expression of CLA-1, CLA-1 BAC transgenic mice had no significant effect on mouse HDL cholesterol. Although coexpression of a human scaffolding protein PDZK1 along with CLA-1 enhanced hepatic CLA-1 expression, it did not affect mouse HDL cholesterol levels, either. However, in the presence of human apoA-1, HDL cholesterol level and size were significantly reduced in CLA-1 transgenic mice, and its reduction was more pronounced in CLA-1/human PDZK1 double transgenic mouse.

Conclusions—We established a mouse model to study human reverse cholesterol transport by expressing CLA-1, human PDZK1, and human apoA-I gene. Our results imply that enhancing CLA-1 expression by human PDZK1 in the liver can modulate HDL cholesterol metabolism and possibly enhance reverse cholesterol transport to prevent the progression of atherosclerosis in human.


Key words: lipoproteins • receptor • transgenic model • apolipoproteins • genetically altered mice